AI Article Synopsis

  • The study aims to evaluate the impact of inhaled prostaglandins on oxygen levels and mortality in critically ill patients with acute respiratory distress syndrome (ARDS), specifically comparing COVID-19-related and non-COVID-19 ARDS.
  • A literature review from 1980 to June 2023 found limited data showing that inhaled prostaglandins might improve oxygenation for some patients but have scarce information on mortality rates, while generally exhibiting a good safety profile.
  • The findings suggest that inhaled prostaglandins could be beneficial for patients with ARDS who struggle with breathing issues, but more research is needed to fully understand their effects on clinical outcomes, particularly regarding mortality.

Article Abstract

Objective: To describe the effect of inhaled prostaglandins on both oxygenation and mortality in critically ill patients with acute respiratory distress syndrome (ARDS), with a focus on safety and efficacy in coronavirus disease 2019 (COVID-19)-associated ARDS and non-COVID-19 ARDS.

Data Sources: A literature search of MEDLINE was performed using the following search terms: , , , All abstracts were reviewed.

Study Selection And Data Extraction: Relevant English-language reports and studies conducted in humans between 1980 and June 2023 were considered.

Data Synthesis: Data regarding inhaled prostaglandins and their effect on oxygenation are limited but show a benefit in patients who respond to therapy, and data pertaining to their effect on mortality is scarce. Concerns exist regarding the formulation of inhaled epoprostenol (iEPO) utilized in addition to modes of medication delivery; however, the limited data surrounding their use have shown a reasonable safety profile. Other avenues and beneficial effects may exist with inhaled prostaglandins, such as use in COVID-19-associated ARDS or non-COVID-19 ARDS patients undergoing noninvasive mechanical ventilation or during patient transport.

Relevance To Patient Care And Clinical Practice: The use of inhaled prostaglandins can be considered in critically ill patients with COVID-19-associated ARDS or non-COVID-19 ARDS who are experiencing difficulties with oxygenation refractory to nonpharmacologic strategies.

Conclusions: The use of iEPO and other inhaled prostaglandins requires further investigation to fully elucidate their effects on clinical outcomes, but it appears these medications may have a potential benefit in COVID-19-associated ARDS and non-COVID-19 ARDS patients with refractory hypoxemia but with little effect on mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1177/10600280231194539DOI Listing

Publication Analysis

Top Keywords

inhaled prostaglandins
24
covid-19-associated ards
16
ards non-covid-19
16
critically ill
12
non-covid-19 ards
12
patients acute
8
acute respiratory
8
respiratory distress
8
distress syndrome
8
prostaglandins oxygenation
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!